Related Experiment Video
Updated: Jun 10, 2025
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Using Hybrid Nanoplatforms to Combine Traditional Anti-Inflammatory Drug Delivery with RNA-Based Therapeutics for
Ana F Almeida1,2, Margarida S Miranda1,2, Rui L Reis1,2
13B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal.
This study developed a dual-drug nanoplatform for targeted inflammation control. The superparamagnetic polymeric micelles effectively delivered anti-inflammatory drugs and microRNAs to macrophages, showing promise for treating chronic inflammatory diseases.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Prolonged inflammation drives diseases like cancer and cardiovascular disorders.
- Current therapies face challenges including non-specific action and short-term effects.
- Macrophages play a central role in initiating and progressing inflammatory responses.
Purpose of the Study:
- To investigate the therapeutic synergy of anti-inflammatory agents targeting macrophages.
- To develop a dual-loading nanoplatform for precise regulation of macrophage functions.
- To enhance the management and resolution of chronic inflammatory conditions.
Main Methods:
- A dual-loading nanoplatform (superparamagnetic polymeric micelles, SPMs) was constructed using palmitic acid-grafted chitosan, superparamagnetic iron oxide nanoparticles, celecoxib, and RNA technologies.
- The SPMs were used to deliver celecoxib and microRNA molecules to naïve (M0φ) and M1-primed macrophages (M1φ).
- Macrophage inflammatory profiles were assessed via gene and protein expression analysis.
Main Results:
- The SPMs efficiently encapsulated and delivered both celecoxib and microRNA molecules.
- Dual-loaded SPMs altered the inflammatory profiles of both M0φ and M1φ.
- The nanoplatform demonstrated potential in modulating initial immune responses and promoting tissue healing.
Conclusions:
- Multi-nanomedicine strategies offer enhanced therapeutic efficacy for inflammatory diseases.
- The developed dual-loading nanoplatform provides a precise and versatile approach for nanotherapeutics delivery.
- This strategy holds promise for more effective management of chronic inflammation and related diseases.
